Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Patent metadata

Field	Value
Publication number	US-11971409-B2
Application number	US-202016892642-A
Country	US
Kind code	B2
Filing date	Jun 4, 2020
Priority date	Jan 15, 2016
Publication date	Apr 30, 2024
Grant date	Apr 30, 2024

Abstract

A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

First claim

What is claimed is:

1. A method of identifying an isolated B cell that produces antibodies capable of binding to a cancer cell-associated antigen comprising:
loading a dissociated cell sample from at least one solid tumor sample obtained from a patient into a microfluidic device having at least one flow region and at least one sequestration chamber comprising an isolation region, wherein the isolation region is fluidically connected to the flow region;
moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and
identifying at least one isolated B cell that produces antibodies capable of binding to a cancer cell-associated antigen by introducing the cancer cell-associated antigen into the microfluidic device.

2. The method of claim 1 , wherein moving the at least one B cell into the at least one isolation region comprises using DEP force to move the at least one B cell.

3. The method of claim 1 , wherein the at least one B cell is moved into the at least one isolation region using gravity and/or localized fluid flow.

4. The method of claim 1 , further comprising:
contacting the at least one B cell with a stimulating agent that stimulates B cell activation.

5. The method of claim 4 , wherein the stimulating agent comprises one or more CD40L+ feeder cells.

6. The method of claim 5 , wherein the one or more CD40L+feeder cells is/are T cells or a derivative thereof.

7. The method of claim 4 , wherein the stimulating agent further comprises a CpG oligonucleotide.

8. The method of claim 4 , wherein the at least one B cells is contacted with the stimulating agent for a period of one to ten days.

9. The method of claim 8 , wherein the at least one B cell is contacted with the stimulating agent substantially continuously for said period of one to ten days.

10. The method of claim 4 , further comprising:
providing culture medium to the at least one B cell, wherein the culture medium comprises one or more growth-inducing agents that promote B cell expansion.

11. The method of claim 10 , wherein the at least one B cells is provided culture medium for a period of one to ten days.

12. The method of claim 10 , wherein the steps of contacting the at least one B cell with the stimulating agent and providing culture medium to the at least one B cell are performed over a substantially coextensive period of time.

13. The method of claim 4 , wherein contacting the at least one B cell with the stimulating agent is performed at least prior to loading the dissociated cell sample into the microfluidic device.

14. The method of claim 4 , wherein contacting the at least one B cell with the stimulating agent is performed at least after moving the at least one B cell into the at least one isolation region.

15. The method of claim 4 , wherein contacting the at least one B cell with the stimulating agent is performed at least during the step of identifying the least one isolated B cell that produces antibodies capable of binding to the cancer cell-associated antigen.

16. The method of claim 1 , wherein introducing the cancer cell-associated antigen into the microfluidic device comprises introducing micro-objects that comprise the cancer cell-associated antigen into the microfluidic device, and further wherein the micro-objects are selected from cells, liposomes, lipid nanorafts, and beads.

17. The method of claim 16 , wherein the micro-objects are cancer cells.

18. The method of claim 17 , wherein the cancer cells exhibit markers that are exhibited by cancer cells from the patient's at least one tumor sample.

19. The method of claim 17 , wherein the cancer cells are isolated from the at least one tumor sample.

20. The method of claim 18 , wherein the cancer cells are isolated from one or more tumor samples obtained from a different patient.

21. The method of claim 17 , wherein the cancer cells are from a cancer cell line.

22. The method of claim 1 , wherein individual cells of the dissociated cell sample are dissociated from the at least one tumor sample by:
a. collagenase plus DNase digestion; and/or
b. a cell dissociator instrument.

Assignees

• Berkeley Lights Inc
• Bruker Cellular Analysis Inc

Inventors

• Chapman Kevin T
• White Mark P
• Wang Xiaohua
• Park Minha
• Stadler Guido K
• Lowe Jr Randall D
• Radstrom Xiao Guan
• Mcewen Jason M
• Wang Gang F
• Fox George L
• Radel Peggy A

Classifications

• G01N33/575 Primary

  for cancer · CPC title

• A61K40/414

  Nervous system antigens · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/13

  Antibody-based · CPC title